Next Article in Journal / Special Issue
A Proposed Clinical Decision Support Architecture Capable of Supporting Whole Genome Sequence Information
Previous Article in Journal / Special Issue
Genetically Guided Statin Therapy on Statin Perceptions, Adherence, and Cholesterol Lowering: A Pilot Implementation Study in Primary Care Patients
Open AccessArticle

Personalized Medicine’s Bottleneck: Diagnostic Test Evidence and Reimbursement

Tufts Center for the Study of Drug Development (Tufts CSDD), Tufts University Medical School, 75 Kneeland Street, Suite 1100, Boston, MA 02111, USA
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2014, 4(2), 163-175; https://doi.org/10.3390/jpm4020163
Received: 25 November 2013 / Revised: 8 March 2014 / Accepted: 26 March 2014 / Published: 4 April 2014
(This article belongs to the Special Issue Bringing Personalized Medicine into Clinical Practice 2013)
Background: Personalized medicine is gradually emerging as a transformative field. Thus far, seven co-developed drug-diagnostic combinations have been approved and several dozen post-hoc drug-diagnostic combinations (diagnostic approved after the drug). However, barriers remain, particularly with respect to reimbursement. Purpose, methods: This study analyzes barriers facing uptake of drug-diagnostic combinations. We examine Medicare reimbursement in the U.S. of 10 drug-diagnostic combinations on the basis of a formulary review and a survey. Findings: We found that payers reimburse all 10 drugs, but with variable and relatively high patient co-insurance, as well as imposition of formulary restrictions. Payer reimbursement of companion diagnostics is limited and highly variable. In addition, we found that the body of evidence on the clinical- and cost-effectiveness of therapeutics is thin and even less robust for diagnostics. Conclusions, discussion: The high cost of personalized therapeutics and dearth of evidence concerning the comparative clinical effectiveness of drug-diagnostic combinations appear to contribute to high patient cost sharing, imposition of formulary restrictions, and limited and variable reimbursement of companion diagnostics. Our findings point to the need to increase the evidence base supportive of establishing linkage between diagnostic testing and positive health outcomes. View Full-Text
Keywords: Personalized medicine; companion diagnostics; reimbursement; cost-effectiveness; coverage with evidence development Personalized medicine; companion diagnostics; reimbursement; cost-effectiveness; coverage with evidence development
Show Figures

Figure 1

MDPI and ACS Style

Cohen, J.P.; Felix, A.E. Personalized Medicine’s Bottleneck: Diagnostic Test Evidence and Reimbursement. J. Pers. Med. 2014, 4, 163-175.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop